Skip links

XENE Xenon Pharmaceuticals Inc Stock Price & News

price target
stage biopharmaceutical company

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Only 2 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. 3 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Advisors Asset Management Inc. acquired a new stake in Xenon Pharmaceuticals in the 1st quarter worth about $66,000. Finally, UBS Group AG boosted its stake in Xenon Pharmaceuticals by 102.1% in the 2nd quarter. UBS Group AG now owns 2,472 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 1,249 shares during the last quarter. 92.49% of the stock is owned by institutional investors and hedge funds. The biotech’s shares, in fact, jumped by as much as 98%, on extremely heavy volume, before 8 a.m. XENE’s stock has seen a -1.32% decrease for the week, with a -2.93% drop in the past month and a -7.96% fall in the past quarter.

– research report

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

Upgrade to Premium to unlock Short-Term Technical Ranking

The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders. Most biotech companies such as Xenon Pharmaceuticals burn cash, and until they make a true shift to commercialization, they trade at lofty valuations. Let’s dive into what Xenon announced and why this is big news for investors in XENE stock. NewsHeater is specialized on the investments in tech sphere. Its specialists are interested in stocks that have been undervalued by different reasons.


They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. As can be expected, positive clinical trial results for one of the company’s key drugs was the driver of today’s move in XENE stock.

XENE Xenon Pharmaceuticals Inc.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.


What analysts recommend for XENE stock, on a scale from 1 to 5. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. While estimates vary, Xenon’s experimental epilepsy drug is expected to compete in a market worth close to $7 billion at present. What’s more, this particular drug market is on track to grow at a compound annual growth rate of approximately 6.6%, according to Coherent Market Insights.

The lesson I refer to is the different approaches to stock investing — choosing either expectations or reality (i.e. fundamentals). Indeed, as with many clinical-stage biotech stocks, such moves can be expected. However, when these moves occur, it’s typically an indication that some sort of major announcement has come down. Xenon Pharmaceuticals delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

How big is Xenon Pharmaceuticals Inc?

You can find more details by visiting the additional pages to how many shares does a company have historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. In one of my past articles, I wrote that even moving from phase-2 to phase-3 clinical trials and getting positive results may take years, not months. I want Xenon Pharmaceuticals to succeed, but the reality right now doesn’t support very high expectations. Monitor XENE stock, but buying it at this price is too bold, too risky, and unjustified based on the true financial performance. Plus, further stock offerings may occur to support further clinical development and trials, and this will not be good news. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

My point, it is too early yet to be optimistic based on real financial metrics. The 2020 Xenon Pharmaceuticals annual report showed revenue growth, reaching a figure of $32.1 million for 2020 compared to $6.8 million for 2019. Key factors that move stocks are earnings expected and real growth; the riskiness of the business; and macro-economic factors such as interest rates, unemployment rate, job, and economic growth. Most of the time, one of these two investment philosophies drives the stock price, and rarely do both point in the same direction.

  • These products and services are usually sold through license agreements or subscriptions.
  • What’s more, this particular drug market is on track to grow at a compound annual growth rate of approximately 6.6%, according to Coherent Market Insights.
  • The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength.
  • We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
  • The technique has proven to be very useful for finding positive surprises.

Live educational sessions using site features to explore today’s markets. Realtime quote and/or trades are not sourced from all markets. Ownerin %Freefloat96.06Avoro Capital Advisor LLC7.83Fidelity Management & Research Co.

Historical Target Prices and Ratings

Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial… Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

3 Stocks to Buy Today, 02/01/2023, According to Top Analysts – TipRanks

3 Stocks to Buy Today, 02/01/2023, According to Top Analysts.

Posted: Wed, 01 Feb 2023 08:00:00 GMT [source]

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Over the past 33 months, XENE’s revenue has gone up $6,342,000.The table below shows XENE’s growth in key financial areas . Revenue growth over the past 12 months for XENON PHARMACEUTICALS INC comes in at -48.83%, a number that bests merely 4.31% of the US stocks we’re tracking.

Xenon Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings. Discuss news and analysts’ price predictions with the investor community. A positive mid-stage trial is powering this biotech stock higher today. This is our shortest-term evaluation and is best used by people with a very short horizon. Analyst Ranking shows you which stocks Wall Street analysts like the most.

Xenon Pharmaceuticals does not have a long track record of dividend growth. Upgrade to MarketBeat All Access to add more stocks to your watchlist. There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amphastar Pharmaceuticals (AMPH – Research Report), Xenon (XENE – Research Report) and BiomX (PHGE – Research Report) with bull… There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT – Research Report), Xenon (XENE – Research Report) and Prometheus Biosciences (RXDX – Research Report) with bull… Measures how much net income or profit is generated as a percentage of revenue.

BHVN Stock: What’s Next For Biohaven After A $12 Billion Buyout … – Investor’s Business Daily

BHVN Stock: What’s Next For Biohaven After A $12 Billion Buyout ….

Posted: Thu, 02 Feb 2023 08:00:00 GMT [source]

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

  • Securities products offered by Open to the Public Investing are not FDIC insured.
  • Get the hottest stocks to trade every day before the market opens 100% free.
  • High-growth stocks tend to represent the technology, healthcare, and communications sectors.

It’s by averaging the closing stock price over the previous 50 trading days. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Enterprise Value is a measure of a company’s total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company’s balance sheet.

The public float for XENE is 59.36M, and at present, short sellers hold a 6.17% of that float. On April 07, 2023, the average trading volume of XENE was 402.48K shares. Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company.

These positive clinical trial results will help Xenon Pharmaceuticals to proceed with further clinical development on the road to commercialization of XEN1101. The book value of a stock is theoretically the amount of money that would be paid to shareholders if the company was liquidated and paid off all of its liabilities. Get the hottest stocks to trade every day before the market opens 100% free. When we switch over and look at the enterprise to sales, we see a ratio of 179.43, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 5.03 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.44.

The volatility ratio for the week is 3.69%, and the volatility levels for the past 30 days are at 4.30% for Xenon Pharmaceuticals Inc. The simple moving average for the last 20 days is 1.12% for XENE stock, with a simple moving average of -3.02% for the last 200 days. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan…

Leave a comment